Financial news reports or official press releases

Danish Biotech Orbis Medicines Raises €90 Million for Oral Macrocycle Drugs Targeting Biologic Therapies

Jan 6, 2025, 04:14 PM

Orbis Medicines, a Danish biotechnology startup, has raised €90 million (approximately $93 million) in a Series A funding round to develop oral macrocycle drugs. The company, incubated by Novo Holdings and co-founded by Sevan Habeshian and Christian Heinis, aims to transform popular biologic therapies into oral medications using macrocyclic peptides, targeting validated blockbuster biologic targets. The funding round was led by New Enterprise Associates (NEA) and included investments from Eli Lilly, Cormorant, the Export and Investment Fund of Denmark, and founding investors Novo Holdings and Forbion. Orbis, which emerged from stealth with €26 million in seed funding last year, is now led by CEO Morten Graugaard Døssing, who previously served as executive chair of the company's board.